BioElectron Technology Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 45

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $210M

BioElectron Technology General Information

Description

Developer of redox drugs designed to discover new approaches to human health and disease. The company's redox drugs detects defects in the mitochondrial proteins, enabling healthcare professionals to treat mitochondrial diseases are genetic disorders.

Contact Information

Formerly Known As
Edison (Pharmaceuticals)
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 350 North Bernardo Avenue
  • Mountain View, CA 94043
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 350 North Bernardo Avenue
  • Mountain View, CA 94043
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioElectron Technology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 25-Oct-2019 $210M Completed Profitable
8. Debt - General 10-Aug-2018 Completed Profitable
7. Later Stage VC (Series G) 27-Mar-2014 Completed Profitable
6. Later Stage VC (Series F) 26-Nov-2012 Completed Profitable
5. Later Stage VC (Series E) 31-Aug-2011 Completed Profitable
4. Later Stage VC (Series D) 15-Apr-2010 Completed Profitable
3. Later Stage VC (Series C) 22-Apr-2009 Completed Profitable
2. Early Stage VC (Series B) 02-Aug-2007 $4.87M $7.67M Completed Profitable
1. Early Stage VC (Series A) 22-Nov-2005 $2.8M $2.8M Completed Profitable
To view BioElectron Technology’s complete valuation and funding history, request access »

BioElectron Technology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view BioElectron Technology’s complete cap table history, request access »

BioElectron Technology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of redox drugs designed to discover new approaches to human health and disease. The company's redox drugs dete
Drug Discovery
Mountain View, CA
45 As of 2015

Cambridge, MA
 

Alameda, CA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioElectron Technology Competitors (43)

One of BioElectron Technology’s 43 competitors is Casma Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Casma Therapeutics Venture Capital-Backed Cambridge, MA
Recyte Therapeutics Formerly VC-backed Alameda, CA
Unity Biotechnology Formerly VC-backed South San Francisco, CA
Oisin Biotechnologies Venture Capital-Backed Seattle, WA
PAQ Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 43 competitors. Get the full list »

BioElectron Technology Patents

BioElectron Technology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2018191732-A1 Methods and compositions for treatment of inflammation and oxidative stress Inactive 14-Apr-2017
US-20180333389-A1 Vitamin e compositions and methods of use therefor Inactive 14-Apr-2017
WO-2018129411-A1 Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders Inactive 06-Jan-2017
WO-2018093957-A1 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications Inactive 15-Nov-2016
JP-2018083799-A 2-substituted amino-naphtho[1,2-d]imidazole-5-one compound or pharmaceutically allowable salts thereof Pending 15-Nov-2016 C07D233/88
To view BioElectron Technology’s complete patent history, request access »

BioElectron Technology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioElectron Technology Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Berg and Berg Enterprises Venture Capital Minority
Mitsui Global Investment Venture Capital Minority
Morningside Group Venture Capital Minority
Sumitomo Pharma Corporation
To view BioElectron Technology’s complete investors history, request access »

BioElectron Technology FAQs

  • When was BioElectron Technology founded?

    BioElectron Technology was founded in 2005.

  • Where is BioElectron Technology headquartered?

    BioElectron Technology is headquartered in Mountain View, CA.

  • What is the size of BioElectron Technology?

    BioElectron Technology has 45 total employees.

  • What industry is BioElectron Technology in?

    BioElectron Technology’s primary industry is Drug Discovery.

  • Is BioElectron Technology a private or public company?

    BioElectron Technology is a Private company.

  • What is the current valuation of BioElectron Technology?

    The current valuation of BioElectron Technology is .

  • What is BioElectron Technology’s current revenue?

    The current revenue for BioElectron Technology is .

  • How much funding has BioElectron Technology raised over time?

    BioElectron Technology has raised $128M.

  • Who are BioElectron Technology’s investors?

    Berg and Berg Enterprises, Mitsui Global Investment, Morningside Group, and Sumitomo Pharma have invested in BioElectron Technology.

  • Who are BioElectron Technology’s competitors?

    Casma Therapeutics, Recyte Therapeutics, Unity Biotechnology, Oisin Biotechnologies, and PAQ Therapeutics are some of the 43 competitors of BioElectron Technology.

  • When was BioElectron Technology acquired?

    BioElectron Technology was acquired on 25-Oct-2019.

  • Who acquired BioElectron Technology?

    BioElectron Technology was acquired by PTC Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process